ArticleBMC plant biology2026
Multi-omics reveals stage-specific mechanisms of Ginseng response to protopanaxadiol-type ginsenosides stress.
Article in BMC plant biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPanax ginseng faces continuous cropping obstacles due to autotoxicity from protopanaxadiol-type ginsenosides. Despite studies on individual ginsenosides being reported, the integrated impact of these compounds across different growth stages requires further investigation.
methodsWe employed multi-omics approaches to elucidate stage-specific molecular mechanisms in ginseng under protopanaxadiol-type ginsenosides stress. Plants were treated with varying concentrations (10-150 mg/L) of protopanaxadiol-type ginsenosides across four growth stages, followed by integrated transcriptomics, extensively targeted metabolomics, and phytohormone-targeted metabolomics analyses with morphological and physiological assessments.
resultsGinseng plants treated with 100 mg/L protopanaxadiol-type ginsenosides showed stage-specific stress responses. Transcriptomics analysis revealed over 20,000 differentially expressed genes across developmental stages (P < 0.05). Significant alterations were observed in pathways related to flavonoids biosynthesis, leading to the identification of 31 key differentially abundant metabolites and 22 critical enzyme genes. Furthermore, 47 differentially expressed genes involved in zeatin biosynthesis and phytohormone signal transduction pathways were identified, potentially regulating the differential accumulation of 8 phytohormones (abscisic acid, jasmonic acid, jasmonoyl-L-isoleucine, salicylic acid, and cytokinins). These molecular responses were putatively associated with enhanced resistance and adaptation to protopanaxadiol-type ginsenosides component stress in ginseng plants. WGCNA identified co-expression modules associated with flavonoid metabolites and phytohormones, providing network-level support for the coordinated regulation between these pathways. Strong correlations were observed between differentially expressed genes and differentially abundant metabolites, suggesting stage-dependent coordinated regulatory networks.
conclusionProtopanaxadiol-type ginsenosides triggered stage-specific regulatory networks in ginseng, especially during the flowering period stage. Parallel activation of flavonoid biosynthesis and phytohormone signaling pathways contributed to the adaptive response to autotoxicity. These findings provided preliminary insights for solving continuous cropping obstacle of ginseng and provided a research strategy for investigating stress response mechanisms of plants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.